Background
Methods
Chlamydia, gonorrhoea, syphilis, trichomoniasis
HSV-2
Bacterial vaginosis (BV)
National peak HIV prevalence
Ethical statement
Statistical analysis
Results
Na
| All countries | Na
| Sub Saharan Africa | |
---|---|---|---|---|
HIV | 170 | 0.4 (0.1–1.6) | 51 | 3.5 (1–7.9) |
HSV-2 | 64 | 27.2 (17.5–50.9) | 20 | 64 (50.9–79.5) |
Chlamydia | 166 | 2.5 (2.2–3.4) | 51 | 2.2(2.1–2.2) |
Gonorrhea | 166 | 0.9 (0.8–1.0) | 51 | 1.1 (1.0–1.2) |
Syphilis | 166 | 0.01 (0.009–0.02) | 51 | 0.02 (0.02–0.02) |
BV | 42 | 18.3 (13.7–29.2) | 13 | 30.3 (25.0–38.1) |
Trichomoniasis | 166 | 2.3 (2.0–3.9) | 51 | 4.1(4.0–4.2) |
HIV | HSV-2 | Chlamydia | Gonorrhoea | Syphilis | Trichomoniasis | |
---|---|---|---|---|---|---|
a) | ||||||
HIV | – | |||||
HSV-2 | .85*** | – | ||||
Chlamydia | −.11 | −.23 | – | |||
Gonorrhoea | .44*** | .58*** | −.69*** | – | ||
Syphilis | .50*** | .67*** | −.03 | .15 | – | |
Trichomoniasis | .75*** | .83*** | −.41*** | .75*** | .56*** | – |
BV | .65*** | .73*** | −.22 | .43 | .50* | .60** |
b) | ||||||
HIV | – | |||||
HSV-2 | .46* | – | ||||
Chlamydia | .34** | .27 | – | |||
Gonorrhoea | −.25 | −.18 | −.62*** | – | ||
Syphilis | .07 | −.02 | .37*** | −.60*** | – | |
Trichomoniasis | .10 | .12 | −.13 | .48*** | −.23 | – |
BV | .29 | .29 | −.05 | .05 | .26 | .15 |